Cupps Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Cupps Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,989	Closed	-$1.97M	–	209
2015 Q4	$1.97M	Buy	2,989 +418	+16%	+$316K	0.28%	97
2015 Q3	$2.02M	Sell	2,571 -575	-18%	-$701K	0.27%	100
2015 Q2	$4.15M	Buy	+3,146	New	+$3.61M	0.4%	86

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cupps Capital Management's ATRA Position: Q1 2016 in Review

Cupps Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2016, closing a stake of 2,989 shares — an estimated $1.97M sold.

Cupps Capital Management first reported a position in ATRA in Q2 2015 and held it in 3 quarters. The position peaked at $4.15M in Q2 2015. 71 funds tracked by Wall St. Rank hold ATRA as of Q1 2016.

Cupps Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2016 after selling out during the quarter.
Cupps Capital Management sold 2,989 Atara Biotherapeutics shares in Q1 2016, an estimated $1.97M.
Cupps Capital Management first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 3 quarters.
Cupps Capital Management's Atara Biotherapeutics position peaked at $4.15M in Q2 2015.
71 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2016.

Based on Cupps Capital Management's 13F filing for Q1 2016, filed 12 May 2016.